| Name | Title | Contact Details |
|---|
Flower One is the largest cannabis cultivator, producer, and full-service brand fulfillment partner in the state of Nevada. By combining more than 20 years of greenhouse operational excellence with best-in-class cannabis operators, Flower One offers consistent, reliable, and scalable fulfillment to a growing number of industry-leading cannabis brands (Cookies, Kiva, Old Pal, Heavy Hitters, Lift Ticket`s, The Clear, and Flower One`s leading in-house brand, NLVO, and more). Flower One currently produces a wide range of products from flower, full-spectrum oils, and distillates to finished consumer packaged goods, including a variety of: pre-rolls, concentrates, edibles, topicals, and more for the top-performing brands in cannabis. Flower One`s Nevada footprint includes the Company`s flagship facility, a 400,000 square-foot high-tech greenhouse and 55,000 square-foot production facility, as well as a second site with a 25,000 square-foot indoor cultivation facility and commercial kitchen. Flower One has built an industry-leading team focused on becoming the first high-quality, low-cost brand fulfillment partner.
Headquartered in Louisville, Kentucky, with nearly $2 billion in annual revenues, PharMerica is one of the largest and fastest growing institutional pharmacy companies in America. We are a premier pharmacy services provider dedicated to providing innovative solutions for customers and patients. At PharMerica, you can choose your career path – hospital pharmacy, long term care pharmacy, corporate and non-clinical opportunities. We employ some of the industry`s best and brightest innovators and clinicians. With more than 100 long-term care pharmacies in over 45 states nationwide, PharMerica employs approximately 5,500 dedicated employees and pharmacy professionals. We offer our staff the opportunity to learn the business and cross train in other areas to provide a catalyst for their career growth within PharMerica. We also recruit our next generation of leaders by hiring new graduates from some of the nation`s top pharmacy and business schools. In addition, we offer educational opportunities through internships and our management training program. As a fast growing organization, we can provide you with the opportunity to kick start your career or advance your skills using some of the industry`s state-of-the-art technology. We foster an environment that encourages our high performers. Because we are a national company, we can provide opportunities for employees that desire to relocate. In addition, we offer a comprehensive benefits package that supports your quality of life.
Zura Bio is a clinical stage biotechnology company focused on developing ZB 168, an anti IL7Rα inhibitor, for the treatment of alopecia areata and other inflammatory diseases.
Osta Biotechnologies Inc. is a Dollard-Des-Ormeaux, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
UroGen Pharma is a biopharmaceutical company that builds novel solutions to revolutionize the way specialty cancers and urologic diseases are treated – because patients deserve better options. Our vision is grounded in our RTGel™ drug delivery technology platform, our promising pipeline, and a collaborative drive for bold results. Our existing technology: the RTGel drug delivery platform has the potential to be applied to a variety of unmet medical needs. RTGel reverse-thermal hydrogel is liquid at lower temperatures and converts to gel form at body temperature, offering the opportunity to make local therapy a more effective treatment. Our promising pipeline: Ranging from pre-clinical to Phase III, we currently have multiple candidates in our pipeline, which are furthering the study of potential treatment advances in urology, uro-oncology, and immunology. Our collaborative drive: We are part of a broad ecosystem of partners who are seeking to improve patient care; these connections are vital to our commitment to offer new pathways and advance solutions. We currently have an exclusive worldwide license agreement with Allergan™ to evaluate the RTGel platform, an early-stage feasibility agreement with Janssen Pharmaceuticals™, and are continually evaluating new opportunities.